Acadia Pharma soars after favorable court ruling in patent dispute
Shares of drug developer Acadia Pharmaceuticals ACAD.O rise 34.2% to over 1-year high of $23.61
U.S. District Court for the District of Delaware has ruled that India's Aurobindo Pharma infringes on two of Acadia Pharmaceuticals' patent claims
The court has rejected Aurobindo's arguments that they are invalid
The companies will meet to discuss next steps and submit a joint letter to the court within 21 days
Acadia will provide an update on its revised stipulation regarding the patent claims within 7 days
Companies must work together to redact sensitive information from the court's opinion and submit a proposed redacted version within 30 days
Including session's move, stock up 28.3% YTD
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
AMD Q1 Earnings: Data Center Revenue Surges 57% Driving Results Above Estimates, Shares Rise Over 16% After Hours

Micron Stock Forecast: Can the AI Memory Super-Cycle Drive MU to $3,000 by 2030?

Dell Stock Analysis: Is It Still Undervalued and the Best AI Infrastructure Play by 2026?

Meta Stock Price Forecast 2026-2030: Can META Hit $1,000?

Vanguard ETF Could Beat the S&P 500 Again in 2026 —— Why Investors Are Paying Attention

Tradingkey







